Latest in: Business
Spanning Europe, the United States, and Asia, investors include the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others Ben Verwaayen appointed as a new Supervisory Board member LEIDEN, the Netherlands. June …
On 13 December 2025, Leyden Labs appeared on Dutch national television in Nieuwsuur. During the broadcast, our CEO Koenraad Wiedhaup and TenneT CEO Manon van Beek discussed the crucial role of innovation in strengthening …
Dutch biotech Leyden Labs has raised a €30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as the Company’s …
The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company’s broadly-protective antibodies to defend against seasonal and pandemic …
Following exciting advancements with new investments, scientific successes with our Mucosal Protection Platform, and clinical progress in our pipeline, we are happy to announce that we are further strengthening our senior leadership team.
It is an honour for us to announce that Leyden Labs is among the select set of groundbreaking companies awarded funding under EU EIC Accelerator program. Only 71 out of 1211 applications were selected …
Leyden Laboratories B.V. announces it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, …
PanFlu is the recipient of the “Monoclonal Antibody Solution of the Year” award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.
CEO Koenraad Wiedhaup recently had the opportunity to share the mission of Leyden Labs with Brad Loncar of Biotech TV during a stop in Leiden on the team’s 2024 European Biotech Tour.
Dr. Ananworanich most recently led influenza vaccine development at Moderna and brings more than 20 years of clinical and industry experience in infectious disease.
We are honored to be included in Insider’s list of inspiring healthcare and biotech companies in 2023.
Leyden Labs announces a $140M Series B financing led by Casdin Capital and GV (formerly Google Ventures) with participation from leading global life science investors. The proceeds accelerate development of products against a broad …
Janssen’s CR9114 is a human monoclonal antibody that protects against influenza A & B. This exclusive license supports Leyden Labs’ mission to optimize mucosal protection against entire viral families to prevent future pandemics.
HollandBIO represents and connects life science companies in the Netherlands and stimulates rapid accessibility of innovation. Over 200 companies are linked through this organization to work towards a better future. Recently, Leyden Labs has …
Earlier this month Labiotech.eu published a Top 15 of Biotech Companies in Amsterdam. They have specifically put together a list of companies seeking to change the world. We are very proud to share this …
InvestInHolland points out the vital role of the Netherlands in today’s global health system by going through the past, present and future of the Dutch pharmaceutical industry. They name Leyden Labs as an example …
Matthew Pillar interviews our CEO, Koenraad Wiedhaup, looking back at when Leyden Labs was founded, Koenraad's unique background and looking ahead to how our products can be complementary to vaccines.
In the Empowered Patient Podcast Karen Jacoda highlights latest innovations in healthcare, pharma and biotech and changing dynamics between patients and physicians in her podcast. For this episode, Karen interviewed our CEO Koenraad, who …
To read the full press release, click below.
Leyden Labs was covered as Emerging Company Profile by Scrip. Sten Stovall discusses in his article how our novel intranasal medicine can potentially target viral families to prevent the next pandemic.
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Contact
Media inquiries
Stay updated
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
Leyden Labs Asia Pte. Ltd.
79 Science Park Drive
#04-05, Cintech IV
Singapore 118264
© Leyden Labs, 2026 | Privacy Statement | Design by Ape to Zebra
